SAN DIEGO, Oct. 25 /PRNewswire/ -- Novocell, Inc., a leading stem cell engineering company, today announced the appointment of Orville G. Kolterman, M.D., Senior Vice President, Clinical & Regulatory Affairs of Amylin Pharmaceuticals, to the company's Board of Directors.
Dr. Kolterman joined Amylin in 1992 and has served as Senior Vice President, Clinical Affairs since February 1997 until present and as Senior Vice President, Regulatory Affairs since August 2005. At Amylin, Dr. Kolterman has been instrumental in the development of the company's first-in-class diabetes medicines, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection.
"Dr. Kolterman's breadth of experience, including the clinical development of successful diabetes therapeutics, will be invaluable to Novocell as we advance the development of our diabetes cell therapy and additional cell therapies," said Alan J. Lewis, President, Chief Executive Officer and Director of Novocell.
"I am pleased to join the Novocell board and look forward to working with the Company to help advance it's innovative platform technologies, including its human embryonic stem cell engineering, cell encapsulation and drug discovery efforts, which hold promise for the treatment of a range of chronic diseases," said Dr. Kolterman.
Prior to Amylin, Dr. Kolterman was Program Director of the General
Clinical Research Center and Medical Director of the Diabetes Center at the
University of California, San Diego (UCSD) Medical Center. He has also
served as Assistant Professor of Medicine in the Endocrinology and
Metabolism Division at the University of Colorado School of Medicine,
Denver and was a member of the Diabetes Control and Complications Trial
Study Group. Dr. Kolterman currently serves as a member of the Epidemiology
of Diabetes Intervention and Complications Study. He is also a
past-president of the California Affiliate of the American Diabetes
Association. Dr. Kolterman r
|SOURCE Novocell, Inc.|
Copyright©2007 PR Newswire.
All rights reserved